Journal ArticleOPEN ACCESS

Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic

OncoImmunology (2016) 5(3)
DOI: 10.1080/2162402X.2015.1078059
6Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

ABSTRACT: Cancer-selective viral replication and delivery of a therapeutic immunomodulating, cancer-selective killing cytokine (mda-7/IL-24) by means of a new Cancer Terminator Virus (CTV) combined with a small molecule BH3 mimetic holds promise for treating both primary and metastatic hormone refractory prostate cancer (CaP).

Author supplied keywords

Cite

CITATION STYLE

APA

Sarkar, S., Pradhan, A., Das, S. K., Emdad, L., Sarkar, D., Pellecchia, M., & Fisher, P. B. (2016). Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic. OncoImmunology, 5(3). https://doi.org/10.1080/2162402X.2015.1078059

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free